Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats

Archives of Medical Research

Volumn 44, Issue 3, 2013, Pages 194-202

  Ávila, Danielle de Lima ^a   Araújo, Glaucy Rodrigues de ^a   Silva, Maisa ^a   Miranda, Pedro Henrique de Amorim ^a   Diniz, Mirla Fiuza ^a   Pedrosa, Maria Lúcia ^a   Silva, Marcelo Eustáquio ^a   Lima, Wanderson Geraldo de ^a   Costa, Daniela Caldeira ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Antioxidant; Inhibitor DPP IV; Oxidative stress; Pancreas

Indexed keywords

CARBONYL DERIVATIVE; CATALASE; GLUCOSE; INSULIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VILDAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL POPULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS INJURY; PANCREAS ISLET BETA CELL; WEIGHT;

ADAMANTANE; ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; CATALASE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; NITRILES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PYRROLIDINES; RATS; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

EID: 84876847293     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.03.004     Document Type: Article

References (55)

1. Atkinson M., Eisenbarth G. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
2. Pospisilik J.A., Martin J., Doty T., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52:741-750.
3. Brubaker P.L., Drucker D.J. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004, 145:2653-2659.
4. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
5. Ehses J.A., Casilla V.R., Doty T., et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogenactivated protein kinase. Endocrinology 2003, 144:4433-4445.
6. Kim S.J., Winter K., Nian C., et al. Glucose dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and downregulation of bax expression. J Biol Chem 2005, 280:22297-22307.
7. Kim S.J., Nian C., Widenmaier S., et al. Glucose-dependent insulinotropic polypeptide (GIP) mediated up-regulation of β-cell antiapoptotic Bcl-2 gene expression is coordinated by cAMP-response element binding protein (CREB) and cAMP-responsive CREB coactivator 2 (TORC2). Mol Cell Biol 2008, 28:1644-1656.
8. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214:829-835.
9. Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
10. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
11. De Meester I., Korom S., Van Damme J., et al. CD26, let it cut or cut it down. Immunol Today 1999, 20:367-375.
12. Pospisilik J.A., Ehses J.A., Doty T., et al. Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol 2003, 524:281-291.
13. Miyagawa J., Miuchi M., Namba M. Incretin-based therapy in patients with type 1 diabetes mellitus. Nihon Rinsho 2001, 69:923-929.
14. Mu J., Woods J., Zhou Y.P., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
15. Kim S.J., Nian C., Doudet D.J., et al. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008, 57:1331-1339.
16. Sudre B., Broqua P., White R.B., et al. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002, 51:1461-1469.
17. Poungvarin N., Lee J.K., Yechoor V.K., et al. Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicity. Diabetologia 2012, 55:1783-1796.
18. Unger R.H., Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985, 28:119-121.
19. Leahy J.L., Bonner-Weir S., Weir G.C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992, 15:442-455.
20. Kaneto H., Katakami N., Kawamori D., et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007, 9:355-366.
21. Piro S., Anello M., Di P.C., et al. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 2002, 51:1340-1347.
22. Cerf M.E. High-fat diet modulation of glucose sensing in beta-cell. Med Sci Monit 2007, 13:RA12-RA17.
23. Ammon H.P., Bumiller G., Düppenbecker H., et al. Pentose phosphate shunt, pyridine nucleotides, glutathione, and insulin secretion of fetal islets. Am J Physiol 1983, 244:E354-E360.
24. Lenzen S., Drinkgern J., Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 1996, 20:463-466.
25. Princípios éticos na experimentação animal do Colégio Brasileiro de Experimentação Animal 1991, Colégio Brasileiro de Experimentação Animal, COBEA, São Paulo.
26. Akarte A.S., Srinivasan B.P., Gandhi S. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: Effects of DPP-IV inhibitor vildagliptin. Eur J Pharmaceut Sci 2012, 45:546-551.
27. Jin H.Y., Liu W.J., Park J.H., et al. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 2010, 40:536-544.
28. Akarte A.S., Srinivasan B.P., Gandhi S., et al. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats. Eur J Pharmaceut Sci 2012, 47:456-463.
29. Burkey B.F., Li X., Bolognese L., et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005, 315:688-695.
30. Akarte A.S., Srinivasan B.P., Gandhi S. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. J Diabetes Complic 2012, 26:266-274.
31. Matsui T., Nishino Y., Takeuchi M., et al. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011, 63:383-388.
32. Lenzen S. The mechanisms of alloxan and streptozotocin-induced diabetes. Diabetologia 2008, 51:216-226.
33. Aebi H. Catalase in vitro. Methods Enzymol 1984, 105:121-126.
34. Beuge J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 1978, 52:302-310.
35. Levine R.L., Williams J.A., Stadtman E.R., et al. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994, 233:346-357.
36. Pauly R.P., Rosche F., Wermann M., et al. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 1996, 271:23222-23229.
37. Deacon C.F., Nauck M.A., Meier J., et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85:3575-3581.
38. Davidson J.A. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010, 85:S27-S37.
39. Evans J.L., Goldfine I.D., Maddux B.A., et al. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction?. Diabetes 2003, 52:1-8.
40. Chen V., Ianuzzo C.D. Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 1982, 60:1251-1256.
41. Rajkumar L., Govindarajulu P. Increased degradation of dermal collagen in diabetic rats. Indian J Exp Biol 1991, 129:1081-1083.
42. Hauggard N. Cellular mechanism of oxygen toxicity. Physiol Rev 1968, 48:311-373.
43. Bhandari U., Jain N., Pillai K.K. Further studies on antioxidant potential and protection of pancreatic beta-cells by Embelia ribes in experimental diabetes. Exp Diabetes Res 2007, 2007:15803.
44. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward?. Cardiovasc Res 2000, 47:410-448.
45. Dahech I., Belghith K.S., Hamden K., et al. Antidiabetic activity of levan polysaccharide in alloxan-induced diabetic rats. Int J Biol Macromol 2011, 49:742-746.
46. Babujanarthanam R., Kavitha P., Mahadeva Rao U.S., et al. Quercitrin a bioflavonoid improves the antioxidant status in streptozotocin: induced diabetic rat tissues. Mol Cell Biochem 2011, 358:121-129.
47. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008, 36:343-347.
48. Venarucci D., Venarucci V., Vallese A., et al. Free radicals: important cause of pathologies refer to ageing. Panminerva Med 1999, 41:335-339.
49. Gardner R., Salvador A., Moradas-Ferreira P. Why does SOD overexpression sometimes enhance, sometimes decrease, hydrogen peroxide production? A minimalist explanation. Free Radic Biol Med 2002, 32:1351-1357.
50. de Haan J.B., Cristiano F., Iannello R., et al. Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum Mol Genet 1996, 5:283-292.
51. Kono Y., Fridovich I. Superoxide radical inhibits catalase. J Biol Chem 1982, 257:5751-5754.
52. Portha B., Tourrel-Cuzin C., Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res 2011, 2011:376509.
53. Butler A.E., Janson J., Bonner-Weir S., et al. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
54. Mathis D., Vence L., Benoist C. β-Cell death during progression to diabetes. Nature 2001, 414:792-798.
55. Cho J.M., Jang H.W., Cheon H., et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Diabetes Res Clin Pract 2011, 91:72-79.